ObjectiveTo analyze the pharmacoeconomics of five angiotensin-converting enzyme inhibitors(ACEIs) in the treatment of essential hypertension(EH).

MethodsFour hundred patients with EH were treated with domestic captopril(group A), joint venture captopril(Capoten) (group B), fosinopril sodium(group C), benazepril hydrochloride(group D) and enalapril maleate(group E), respectively(80 cases in each group).The systolic blood pressur(SBP) and diastolic blood pressure(DBP) levels in five groups before and after treatment were measured, and the therapeutic effects and costs of five kinds of ACEIs for EH were compared.

ResultsBefore treatment, the differences of the levels of SBP and DBP among five groups were not statistically significant(P>0.05).After treatment, the levels of SBP and DBP in each group were significantly lower than those before treatment(P < 0.01), and which in groups C, D and E were significantly lower than those in groups A and B(P < 0.05 to P < 0.01).The differences of the therapeutic effects among five groups were statistically significant(P < 0.01), and the therapeutic effects in C, groups D and E were better than those in groups A and B(P < 0.05).The differences of the cost and effects among five groups were statistically significant(P < 0.01), the cost, effects and ratio of C/E in B, groups C and A were higher than those in groups A and E, and the value of △C/△E in groups C and D were higher than that in group E(P < 0.05 to P < 0.01).The differences of the incidence rates of adverse reactions among five groups were statistically significant(P < 0.01), and the total incidence rates of adverse reactions in groups C and E were lower than that in groups A and B(P < 0.05).

ConclusionsThe enalapril maleate in the treatment of EH has high total efficiency, safety and drug economy.